AR121982A1 - Moduladores del receptor ccr6 - Google Patents

Moduladores del receptor ccr6

Info

Publication number
AR121982A1
AR121982A1 ARP210101183A ARP210101183A AR121982A1 AR 121982 A1 AR121982 A1 AR 121982A1 AR P210101183 A ARP210101183 A AR P210101183A AR P210101183 A ARP210101183 A AR P210101183A AR 121982 A1 AR121982 A1 AR 121982A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
mono
unsubstituted
hydroxy
Prior art date
Application number
ARP210101183A
Other languages
English (en)
Inventor
Oliver Allemann
Eva Caroff
Alexia Chavanton-Arpel
Andrew Croxford
Francis Hubler
Loc Jacob
Emmanuel Meyer
Sylvia Richard-Bildstein
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of AR121982A1 publication Critical patent/AR121982A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), donde A representa un heteroarilo de 6 miembros que contiene uno a tres átomos de nitrógeno en forma de anillo, donde dicho heteroarilo de 6 miembros está independientemente sin sustituir, mono-, di- o tri-sustituido, donde los sustituidos, de haberlo, es (son) independientemente seleccionado(s) de halógeno; ciano; hidroxi-C₁₋₆-alquilo que además está opcionalmente sustituido con uno a tres átomos de flúor; C₁₋₅-alquilo que está sin sustituir o mono-sustituido con C₁₋₃-alcoxi; C₃₋₆-cicloalquilo que está opcionalmente fusionado con un anillo de piridina, donde dicho C₃₋₆-cicloalquilo está sin sustituir o mono-sustituido con hidroxi; -O-RO¹, donde RO¹ representa C₃₋₆-cicloalquilo o pirrolidinil que está independientemente sin sustituir o mono-sustituido con C₁₋₃-alquilo o C₁₋₄-alquilo-carbonilo; fenil-L¹-, donde dicho fenil está sin sustituir o mono-sustituido con flúor, C₁₋₄-alcoxi-carbonilo, o hidroxi-C₁₋₄-alquilo; donde -L¹- representa una unión, oxígeno, o el grupo -CH₂-O-; C₄₋₆-heterociclilo que contiene uno o dos heteroátomos en forma de anillo independientemente seleccionados de entre nitrógeno y oxígeno, donde dicho C₄₋₆-heterociclilo está sin sustituir, mono-, o di-sustituido con oxo, hidroxi, C₁₋₃-alquilo, C₁₋₄-alquilo-carbonilo, o C₁₋₄-alcoxi- carbonilo; un heteroarilo de 5 miembros que contiene uno o dos átomos de nitrógeno en forma de anillo, donde dicho heteroarilo de 5 miembros está sin sustituir o mono-sustituido con C₁₋₃-alquilo; -NRN¹RN² donde RN¹ representa hidrógeno y RN² representa C₁₋₃-alquilo-carbonilo o hidroxi-C₁₋₃-alquilo-carbonilo; indolilo; pirrolopiridinilo; N-(C₁₋₃-alquilo)-amino-carbonilo-oxi; o 1-hidroxi-1-C₃₋₅-cicloalquilo-1-(piridinil)-metilo; C₃₋₅-alquilo que está sustituido con hidroxi y RA¹, donde dichos sustituyentes están ambos en la posición 3 con respecto al punto de unión de dicho C₃₋₅-alquilo al resto de la molécula; donde RA¹ representa tetrahidropiranoil; fenil que está sin sustituir o mono-sustituido con flúor o con C₁₋₃-alcoxi; heteroarilo de 5 o de 6 miembros que contiene uno o dos heteroátomo(s) de anillo siendo independientemente seleccionado de entre nitrógeno o azufre, donde dicho heteroarilo de 5 ó 6 miembros está independientemente sin sustituir, mono- o di- sustituido, y donde los sustituyente(s), de haberlos, es(son) independientemente seleccionado de entre C₁₋₃-alquilo, C₃₋₅-cicloalquilo, o C₁₋₃-alcoxi; o indolilo; pirrolopiridinilo; C₃₋₅-alquenilo que está sin sustituir o mono-sustituido con hidroxi; C₄₋₆-cicloalquenilo que está sin sustituir, mono-, o di-sustituido con C₁₋₃-alquilo, oxo, o hidroxi, donde opcionalmente un átomo de carbono de anillo de dicho C₄₋₆-cicloalquenilo es reemplazado por un átomo de oxígeno; C₃₋₆-cicloalquilo que está sin sustituir, mono-, o di-sustituido con C₁₋₃-alquilo, hidroxi o hidroxi-C₁₋₃-alquilo, donde opcionalmente un átomo de carbono de anillo de dicho C₃₋₆-cicloalquilo es reemplazado por un átomo de oxígeno; -O-RO², donde RO² representa C₁₋₄-alquilo; C₂₋₅-alquilo que es mono-sustituido con hidroxi o C₁₋₃-alcoxi; -L²-CY², donde -L²- independientemente representa una unión, -CH₂-, o -CH₂-CH₂-; y CY² independientemente representa fenil que está sin sustituir o mono-sustituido con hidroxi-C₁₋₃-alquilo; bencil-oxi; heteroarilo de 5 a 6 miembros que contiene uno a tres heteroátomo(s) de anillo siendo independientemente seleccionados de entre nitrógeno, oxígeno, o azufre, donde dicho heteroarilo de 5 ó 6 miembros está independientemente sin sustituir, mono- o di- sustituido; donde los sustituyente(s), de haberlos, es(son) independientemente seleccionados de entre C₁₋₃-alquilo o C₁₋₃-cicloalquilo; C₃₋₆-cicloalquilo, donde opcionalmente un átomo del anillo de carbono es reemplazado por un heteroátomo seleccionado de entre oxígeno y nitrógeno; donde dicho C₃₋₆-cicloalquilo está sin sustituir, mono-, o di-sustituido, donde el o los sustituyente(s) es o son seleccionados de entre C₁₋₃-alquilo, hidroxi, fluoro, oxo, C₁₋₃-alquilo-carbonilo y C₁₋₃-alcoxi; benzooxaxolonilo; cromanilo; -C&
ARP210101183A 2020-04-30 2021-04-30 Moduladores del receptor ccr6 AR121982A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2020062103 2020-04-30

Publications (1)

Publication Number Publication Date
AR121982A1 true AR121982A1 (es) 2022-07-27

Family

ID=75728860

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101183A AR121982A1 (es) 2020-04-30 2021-04-30 Moduladores del receptor ccr6

Country Status (12)

Country Link
US (1) US20230174514A1 (es)
EP (1) EP4143179A1 (es)
JP (1) JP2023523300A (es)
KR (1) KR20230005938A (es)
CN (1) CN115551841A (es)
AR (1) AR121982A1 (es)
AU (1) AU2021266148A1 (es)
BR (1) BR112022021976A2 (es)
CA (1) CA3177335A1 (es)
IL (1) IL297675A (es)
TW (1) TW202200560A (es)
WO (1) WO2021219849A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
TW202325278A (zh) 2021-10-26 2023-07-01 瑞士商愛杜西亞製藥有限公司 Ccr6受體調節劑
AR127486A1 (es) 2021-10-28 2024-01-31 Idorsia Pharmaceuticals Ltd Moduladores del receptor ccr6

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28141A (en) 1860-05-08 Stephen l
US3479370A (en) 1966-08-08 1969-11-18 Robins Co Inc A H Esters of 1-substituted-3-disubstituted-pyrrolidinemethanols
US3489769A (en) 1968-06-20 1970-01-13 Robins Co Inc A H 1-substituted-3-aroyl-pyrrolidines
US3499002A (en) 1968-06-20 1970-03-03 Robins Co Inc A H 1-carbamoyl-3-aroylpyrrolidines
US3542807A (en) 1969-04-14 1970-11-24 Robins Co Inc A H 1-(omega-benzoylalkyl)-3-substituted pyrrolidines
US3651085A (en) 1969-04-14 1972-03-21 Robins Co Inc A H 1-(omega-benzoylalkyl)-3-substituted pyrrolidines
US3694458A (en) 1970-08-31 1972-09-26 Robins Co Inc A H 1-nitrosopyrrolidines
US5278045A (en) 1990-02-28 1994-01-11 Du Pont Merck Pharmaceutical Company Method and compositions to screen compounds for enhancement of the cholinergic, dopaminergic and serotonergic function
FR2775477B1 (fr) 1998-02-27 2000-05-19 Union Pharma Scient Appl Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique
DE10144872A1 (de) 2001-09-12 2003-03-27 Bayer Cropscience Gmbh Azetidinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
UY29610A1 (es) 2005-06-21 2007-01-31 Cancer Rec Tech Ltd Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
EP1937068A4 (en) 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
CA2675942C (en) 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2010131147A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
FR2981934B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CN103588697B (zh) 2012-08-14 2017-09-15 中国科学院上海药物研究所 一类2，5‑二取代苯磺酰胺类化合物及其制备方法和用途
PE20150778A1 (es) 2012-10-16 2015-05-23 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de ror-gamma-t
CN103800309A (zh) 2012-11-15 2014-05-21 中国科学院上海药物研究所 金精三羧酸在制备靶向趋化因子受体的药物中的用途
BR112016008158A2 (pt) 2013-10-15 2017-10-03 Janssen Pharmaceutica Nv Moduladores de ror-gama-t de quinolinila ligados a metileno
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9340509B2 (en) 2013-12-02 2016-05-17 Chemocentryx, Inc. CCR6 compounds
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
KR20200037857A (ko) 2017-08-14 2020-04-09 알러간, 인코포레이티드 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
JP7355758B2 (ja) 2018-01-26 2023-10-03 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びその使用
GEP20237476B (en) 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors

Also Published As

Publication number Publication date
JP2023523300A (ja) 2023-06-02
US20230174514A1 (en) 2023-06-08
AU2021266148A1 (en) 2023-01-05
CN115551841A (zh) 2022-12-30
EP4143179A1 (en) 2023-03-08
BR112022021976A2 (pt) 2022-12-13
IL297675A (en) 2022-12-01
CA3177335A1 (en) 2021-11-04
TW202200560A (zh) 2022-01-01
WO2021219849A1 (en) 2021-11-04
KR20230005938A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
AR121982A1 (es) Moduladores del receptor ccr6
AR112682A1 (es) Compuestos herbicidas
AR116666A1 (es) Compuestos heterocíclicos
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR111241A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR075854A1 (es) Inhibidores de beta- secretasa
PE20211779A1 (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
PE20130155A1 (es) Derivados de ariletinilo
AR119943A1 (es) Compuestos heterocíclicos
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
PE20230560A1 (es) Inhibidores de rip1k
AR098909A1 (es) Compuesto heterocíclico
AR088449A1 (es) Benzilindazoles sustituidos
AR113888A1 (es) Derivados de indol macrocíclicos sustituidos
AR113886A1 (es) Derivados de indol macrocíclicos
AR108778A1 (es) Compuestos antibacterianos
AR109635A1 (es) Mezcla aditiva
PE20181885A1 (es) Derivados de indolin-2-ona
PE20091678A1 (es) Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176
ES2568909T3 (es) Novedosos compuestos antagonistas del receptor de la neuroquinina 1
AR066603A1 (es) Derivados de arilamida pirimidona
CO5700777A2 (es) Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina